Clindamycin

Generic Name: Clindamycin

Brand Names: Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃ClN_₂O_₅S

CAS Number: 18323-44-9

Unique Ingredient Identifier: 3U02EL437C

Background: Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamy...

Indication: In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purp...

Associated Conditions: Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci

Associated Therapies: -

Clinical Trials

Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis

Phase 3

Completed

Conditions: Bacterial Vaginosis

Interventions: Drug: Dequalinium chloride
Drug: Clindamycin

First Posted Date: 2010-05-18

Last Posted Date: 2010-05-18

Lead Sponsor: Medinova AG

Target Recruit Count: 321

Registration Number: NCT01125410

Locations: 🇧🇪
AZ Ziekenhuis Oost-Limburg, Genk, Belgium
🇸🇰
JLF UK a MFN, Martin, Slovakia
🇨🇿
Charles University, Prague, Czech Republic

and more 11 locations

Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"

Phase 2

Completed

Conditions: Staphylococcal Infection

Interventions: Other: Placebo
Drug: Clindamycin
Drug: Cephalexin
Drug: Trimethoprim-sulfamethoxazole

First Posted Date: 2008-08-08

Last Posted Date: 2015-02-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2265

Registration Number: NCT00729937

Locations: 🇺🇸
University of California Los Angeles - Olive View Medical Center, Sylmar, California, United States
🇺🇸
Maricopa Medical Center - Emergency Medicine, Phoenix, Arizona, United States
🇺🇸
Johns Hopkins University at Mount Washington - Emergency Medicine, Baltimore, Maryland, United States

and more 2 locations

Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Phase 2

Completed

Conditions: Staphylococcal Infection

Interventions: Drug: Trimethoprim-sulfamethoxazole
Other: Placebo
Drug: Clindamycin

First Posted Date: 2008-08-08

Last Posted Date: 2016-03-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1310

Registration Number: NCT00730028

Locations: 🇺🇸
Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
🇺🇸
The University of Chicago - Comer Children's Hospital - Infectious Diseases, Chicago, Illinois, United States
🇺🇸
San Francisco General Hospital - Infectious Diseases, San Francisco, California, United States

and more 3 locations

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-110
Drug: Vehicle
Drug: Benzoyl peroxide
Drug: Clindamycin

First Posted Date: 2008-04-22

Last Posted Date: 2008-04-22

Lead Sponsor: Dow Pharmaceutical Sciences

Target Recruit Count: 1414

Registration Number: NCT00664248

Locations: 🇺🇸
Advanced Clinical Research - Jordan Valley, West Jordan, Utah, United States
🇺🇸
International Dermatology Research, Inc., Miami, Florida, United States
🇺🇸
The Nevada Center for Dermatology, Reno, Nevada, United States

and more 32 locations

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-110
Drug: Vehicle
Drug: Benzoyl peroxide
Drug: Clindamycin

First Posted Date: 2008-04-22

Last Posted Date: 2008-04-22

Lead Sponsor: Dow Pharmaceutical Sciences

Target Recruit Count: 1399

Registration Number: NCT00663286

Locations: 🇺🇸
Central Sooner Research, Norman, Oklahoma, United States
🇺🇸
Derm Center of Augusta, Augusta, Georgia, United States
🇺🇸
Webster Dermatology, PA, Hockessin, Delaware, United States

and more 29 locations

Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis

Phase 4

Completed

Conditions: Pregnancy

Interventions: Drug: Clindamycin
Drug: Placebo

First Posted Date: 2008-03-25

Last Posted Date: 2014-01-23

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 3105

Registration Number: NCT00642980

Locations: 🇫🇷
Hopital Jeanne de Flandre, Lille, France

Vaginal Infection Study

Phase 3

Completed

Conditions: Vulvovaginitis
Vaginitis

Interventions: Drug: clindamycin phosphate/butoconazole nitrate
Drug: butoconazole nitrate
Drug: clindamycin phosphate

First Posted Date: 2008-02-15

Last Posted Date: 2012-03-05

Lead Sponsor: Lumara Health, Inc.

Target Recruit Count: 1443

Registration Number: NCT00616330

Locations: 🇺🇸
Northern Indiana Womens Health Research, South Bend, Indiana, United States
🇺🇸
Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States
🇺🇸
Medford Women's Clinic, LLP, Medford, Oregon, United States

and more 127 locations